ReviewLeukemia2025

Fixed-duration therapy of chronic lymphocytic leukemia with venetoclax and Bruton tyrosine kinase inhibitors: an insight into differences between ibrutinib and acalabrutinib.

Alessandra Tedeschi et al.PubMed ↗Publisher ↗

No numbers read from the abstract.